2022.06.07 -- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of ULTOMIRIS? (ravulizumab-cwvz) to include children ……
May 27, 2022 -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that the U.S. Food and Drug Administration (FDA) has approved NURTEC? ODT (rimegepant 75 mg) for the preventive treatment of migr……
May 23, 2022 -- Heron Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNRELEF (bupivacaine and meloxicam) extended-release solution for use in adults for soft tissue or p……
April 26, 2022—Bristol Myers Squibb today announced that Opdivo (nivolumab) (injection for intravenous use), in combination with fluoropyrimidine- and platinum-containing chemotherapy, was approved by the U.S. Food and D……
April 02, 2022-- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced t……
March 30, 2022—Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos? (daunorubicin and cytarabine) to include a new indication to tr……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
